Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -27.62% is 22% above its 5-year average of -35.27%, around the middle of its 5-year range (-63.81%–-5.26%).
As of the fiscal period ended Tuesday, June 30, 2026. 11.45% above its 12-month average of -31.20%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -27.62%.
RETURN ON INVESTED CAPITAL (ROIC)
-27.62%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-31.20%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-28.24%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-35.27%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+11.45%
CURRENT VS 3Y AVG
+2.19%
CURRENT VS 5Y AVG
+21.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.17%
median of 816 covered companies
CURRENT VS SECTOR MEDIAN
+21.46%
vs the sector median at left
Fulcrum Therapeutics, Inc.
Market Cap
$281.92M
Return on Invested Capital (ROIC)
-27.62%
TTM Avg
-31.20%
3Y Avg
-28.24%
5Y Avg
-35.27%
Market Cap
$280.91M
Return on Invested Capital (ROIC)
-15.69%
TTM Avg
-4.06%
3Y Avg
-9.73%
5Y Avg
-12.88%
Market Cap
$283.18M
Return on Invested Capital (ROIC)
-61.10%
TTM Avg
-38.45%
3Y Avg
-31.16%
5Y Avg
-81.63%
Market Cap
$284.80M
Return on Invested Capital (ROIC)
-129.90%
TTM Avg
-509.42%
3Y Avg
-303.54%
5Y Avg
-247.13%
Market Cap
$285.55M
Return on Invested Capital (ROIC)
-49.76%
TTM Avg
-54.76%
3Y Avg
-73.23%
5Y Avg
-84.98%
Market Cap
$285.74M
Return on Invested Capital (ROIC)
-20.40%
TTM Avg
-43.02%
3Y Avg
-57.92%
5Y Avg
-48.43%
Market Cap
$287.37M
Return on Invested Capital (ROIC)
-14.06%
TTM Avg
-26.07%
3Y Avg
-28.37%
5Y Avg
-26.89%
Market Cap
$291.45M
Return on Invested Capital (ROIC)
-136.49%
TTM Avg
-130.82%
3Y Avg
-85.38%
5Y Avg
-76.42%
Market Cap
$272.17M
Return on Invested Capital (ROIC)
-58.72%
TTM Avg
-52.25%
3Y Avg
-49.23%
5Y Avg
-41.07%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $281.92M | -27.62% | -31.20% | -28.24% | -35.27% |
| Aurora Cannabis Inc. (ACB)vs › | $280.91M | -15.69% | -4.06% | -9.73% | -12.88% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $283.18M | -61.10% | -38.45% | -31.16% | -81.63% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $284.80M | -129.90% | -509.42% | -303.54% | -247.13% |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | -49.76% | -54.76% | -73.23% | -84.98% |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.74M | -20.40% | -43.02% | -57.92% | -48.43% |
| Standard BioTools Inc. (LAB)vs › | $287.37M | -14.06% | -26.07% | -28.37% | -26.89% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $291.45M | -136.49% | -130.82% | -85.38% | -76.42% |
| Fate Therapeutics, Inc. (FATE)vs › | $272.17M | -58.72% | -52.25% | -49.23% | -41.07% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.25M | -48.92% | -66.11% | -56.53% | -47.58% |
ROIC
-27.6%
ROE
-27.4%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -27.62% |
| 2026-03-31 | -25.69% |
| 2025-12-31 | -24.00% |
| 2025-09-30 | -40.11% |
| 2025-06-30 | -38.56% |
| 2025-03-31 | -5.26% |
| 2024-12-31 | -8.77% |
| 2024-09-30 | -11.52% |
| 2024-06-30 | -11.64% |
| 2024-03-31 | -50.27% |
| 2023-12-31 | -44.95% |
| 2023-09-30 | -41.42% |
| 2023-06-30 | -37.34% |
| 2023-03-31 | -37.01% |
| 2022-12-31 | -53.61% |
| 2022-09-30 | -45.89% |
| 2022-06-30 | -59.55% |
| 2022-03-31 | -44.04% |
| 2021-12-31 | -37.56% |
| 2021-09-30 | -32.04% |
| 2021-06-30 | -63.81% |
| 2021-03-31 | -52.19% |
| 2020-12-31 | -69.63% |
| 2020-09-30 | -60.74% |
| 2020-06-30 | -52.11% |
| 2020-03-31 | -81.55% |
| 2019-12-31 | -85.67% |
| 2019-09-30 | -71.69% |
| 2019-06-30 | -117.43% |
| 2019-03-31 | -89.45% |
| 2018-12-31 | -41.08% |
